Standing Order
Pfizer Inc.

Dashboard

Pfizer Inc.

PFENYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$140B
Price$24.5452w $23.29 – $28.55
Conviction3/ 5
Revenue (TTM)$63.3B
Revenue growth YoY+1.4%
P/E (trailing)18.7
Gross margin69.3%
Operating margin23.4%
Net margin11.8%
52w price change+2.4%
Next earningsAug 4, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Jul 16
    Ownership changeSEC

    Form 4 insider ownership change report filed 2026-07-16.

  • Jul 13
    Ownership changeSEC

    Form 4 insider transaction report filed.

  • Jul 1
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider beneficial ownership change filing.

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider transaction filing dated 2026-06-30.

  • Jun 30
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership.

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider beneficial ownership change filing.

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 18
    OtherSEC

    Pfizer files 8-K under item 7.01 (Regulation FD disclosure).

  • Jun 18
    LeadershipSEC

    Pfizer 8-K reports item 5.02 officer or director change with exhibits.

  • Jun 16
    Ownership changeSEC

    SEC Form 4 insider transaction filing for change in beneficial ownership.

  • Jun 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 5
    Trial initiationClinicalTrials.gov

    Phase 2 trial NCT07475806 (enfortumab vedotin + pembrolizumab, muscle-invasive bladder cancer) status updated to RECRUITING; sponsored by Astellas.

  • Jun 4
    Trial initiationClinicalTrials.gov

    Seagen (Pfizer subsidiary) phase 3 trial (NCT05253651) of tucatinib + trastuzumab + mFOLFOX6 in HER2+ mCRC recruiting

  • Jun 4
    Trial initiationClinicalTrials.gov

    Pfizer initiates Phase 1/2 trial NCT07421700 of PF-08634404 alone or with enfortumab vedotin in urothelial cancer; recruiting.

  • Jun 1
    Ownership changeSEC

    SEC Form 4 insider transaction filing for Pfizer Inc.

  • Jun 1
    OtherClinicalTrials.gov

    Phase 2 trial (NCT06003231) of disitamab vedotin in HER2+ solid tumors updated to ACTIVE_NOT_RECRUITING (Seagen/Pfizer sponsor).

  • May 28
    Trial initiationClinicalTrials.gov

    Phase 4 safety study (NCT06862219) of Enfortumab Vedotin recruiting in India for urothelial cancer; sponsored by Astellas

  • May 27
    OtherClinicalTrials.gov

    Seagen (Pfizer subsidiary) phase 3 trial NCT06012435 for SGN-B6A vs Docetaxel in NSCLC status updated to ACTIVE_NOT_RECRUITING

Not financial advice — research and opinion only. Disclosures